MYGN
Myriad Genetics, Inc.NASDAQHealthcare$4.75+3.49%OpenMarket Cap: $444.2M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.20
P/S
0.54
EV/EBITDA
-1.26
DCF Value
$-18.41
FCF Yield
-3.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
69.9%
Operating Margin
-31.7%
Net Margin
-44.4%
ROE
-79.8%
ROA
-72.9%
ROIC
-41.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $209.8M | 70.0% | $120.0M | $-7.9M | $-0.08 | — |
| FY 2025 | $824.5M | 69.9% | $-139.3M | $-365.9M | $-3.96 | — |
| Q3 2025 | $205.7M | 69.9% | $-23.3M | $-27.4M | $-0.29 | — |
| Q2 2025 | $213.1M | 71.2% | $-329.2M | $-330.5M | $-3.57 | — |
| Q1 2025 | $195.9M | 68.5% | $-29.0M | $-100.0K | $-0.00 | — |
| Q4 2024 | $210.6M | 71.7% | $-39.0M | $-42.5M | $-0.47 | — |
| FY 2024 | $837.6M | 69.9% | $-123.5M | $-127.3M | $-1.41 | — |
| Q3 2024 | $213.3M | 70.2% | $-20.0M | $-22.1M | $-0.24 | — |
| Q2 2024 | $211.5M | 69.6% | $-36.5M | $-36.7M | $-0.41 | — |
| Q1 2024 | $202.2M | 68.1% | $-27.9M | $-26.0M | $-0.29 | — |
| Q4 2023 | $196.6M | 68.7% | $-31.4M | $-31.2M | $-0.36 | — |
| FY 2023 | $753.2M | 68.6% | $-257.4M | $-263.3M | $-3.18 | — |